Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant

0 avis

Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant

Archive ouverte

Edité par CCSD ; American Medical Association -

International audience. This cohort study examines safety and antibody responses after 1 and 2 doses of BNT162b2 mRNA vaccine in recipients of allogeneic hematopoietic stem cell transplant (HSCT).

Langue: en

Indexation

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

Gestion des toxicités des lymphocytes T exprimant un récepteur à l’antigène chimérique (CAR-T cells)

Archive ouverte | Le Bourgeois, Amandine | CCSD

International audience

Effectiveness of a third dose of BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccine over a 6‐month follow‐up period in allogenic hematopoietic stem cells recipients

Archive ouverte | Chevallier, Patrice | CCSD

International audience. This study reports the effectiveness of three injections of BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccine in 141 Allo‐HSCT recipients with a median follow‐up of 6 months post‐third shot. We demonstra...

Addition of ATG to non-myeloablative peripheral blood haploidentical transplant with PTCY decreases acute GVHD rates and improves GVHD-relapse free survival

Archive ouverte | Jullien, Maxime | CCSD

International audience

Chargement des enrichissements...